Eyepoint Pharmaceuticals, INC Schedule 13G passive stakes

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 5.71% of EyePoint, Inc.'s common stock as of June 30, 2026.

Vanguard Capital Management has reported a beneficial ownership stake of 5.03% in EyePoint Inc., crossing the 5% threshold requiring disclosure.

Commodore Capital LP, along with affiliated entities and individuals, has reported beneficial ownership of 4,250,000 shares, representing 5.1% of EyePoint, Inc.'s common stock.

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 3,300,000 shares, representing 3.96% of EyePoint, Inc.'s common stock as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for EyePoint Inc, reporting 0% beneficial ownership following an internal corporate realignment.

Paradigm BioCapital Advisors LP and related entities have disclosed a 5.1% beneficial ownership stake in EyePoint, Inc. common stock.

Adage Capital Management, L.P. and its principals have reported a 5.68% beneficial ownership stake in EyePoint, Inc., holding 4,700,000 shares as of December 31, 2025.

Cormorant Asset Management, LP and Bihua Chen have disclosed a 9.98% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., holding 8,265,000 shares.

Adage Capital Management, L.P. and its principals have reported an 8.07% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., holding 5,559,782 shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.5% beneficial ownership stake in EyePoint Pharmaceuticals, Inc. common stock as of September 30, 2025.

Adage Capital Management, L.P. and its principals reported a 9.88% beneficial ownership stake in EyePoint Pharmaceuticals, Inc. as of June 30, 2025.

Federated Hermes, Inc. and affiliated entities have disclosed a 6.68% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., held in the ordinary course of business.

RA Capital Management, along with its affiliates Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., has filed an amendment to their Schedule 13G, disclosing a 4.7% beneficial ownership stake in EyePoint Pharmaceuticals, Inc. as of December 31, 2024.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, reported a beneficial ownership of 8.42% in EyePoint Pharmaceuticals, Inc. as of December 31, 2024.

Franklin Resources, Inc. and its affiliates have filed an amendment to their Schedule 13G, disclosing a continued passive beneficial ownership of 6.1% in EyePoint Pharmaceuticals, Inc. as of December 31, 2024.